Stock Market Reviews

SPRB (Spruce Biosciences, Inc.) News

Get the latest news, insights, and market updates on SPRB (Spruce Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
  SOUTH SAN FRANCISCO, Calif., November 10, 2025--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2025 and provided corporate updates.
  Nov 10, 2025 - $SPRB
• What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?
  Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Oct 15, 2025 - $SPRB
• Spruce Biosciences Announces $50.0 Million Private Placement Financing
  SOUTH SAN FRANCISCO, Calif., October 08, 2025--Spruce Biosciences Announces $50.0 Million Private Placement Financing
  Oct 8, 2025 - $SPRB
• This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.
  The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.
  Oct 7, 2025 - $SPRB
• Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
  SOUTH SAN FRANCISCO, Calif., October 06, 2025--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).
  Oct 6, 2025 - $SPRB
• Why Spruce Biosciences Just Skyrocketed Almost 1,400%
  Spruce Biosciences skyrocketed almost 1,400% late Monday after the FDA granted its rare disease drug a breakthrough designation.
  Oct 6, 2025 - $SPRB
• Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
  SOUTH SAN FRANCISCO, Calif., September 15, 2025--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol "SPRB" and CUSIP 85209E 208.
  Sep 15, 2025 - $SPRB
• Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
  SOUTH SAN FRANCISCO, Calif., August 14, 2025--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2025 and provided corporate updates.
  Aug 14, 2025 - $SPRB
• Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
  SOUTH SAN FRANCISCO, Calif., August 14, 2025--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced results from a long-term data integration of tralesinidase alfa enzyme replacement therapy (TA-ERT) clinical program in patients with Sanfilippo Syndrome Type B (MPS IIIB).
  Aug 14, 2025 - $SPRB
• Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
  Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $SPRB